• Gio. Mag 30th, 2024

Janus kinase

  • Home
  • Moderately to everely active Ulcerative Colitis, European Commission approves Pfizer’s etrasimod (Velsipity®)

Moderately to everely active Ulcerative Colitis, European Commission approves Pfizer’s etrasimod (Velsipity®)

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and…